Sam­sung Bi­o­log­ics, TG Ther­a­peu­tics ink deal to mass pro­duce MS hope­ful ubli­tux­imab

As Sam­sung Bi­o­log­ics looks to dra­mat­i­cal­ly scale its pro­duc­tion with a $2 bil­lion “su­per plant” in In­cheon, South Ko­rea, it’s sign­ing on part­ners to fill its man­u­fac­tur­ing sched­ule. Now, Sam­sung and TG Ther­a­peu­tics will work to­geth­er on man­u­fac­tur­ing MS hope­ful ubli­tux­imab.

“With the re­cent pos­i­tive UL­TI­MATE I and II MS Phase 3 stud­ies, we re-eval­u­at­ed our sup­ply needs and were very pleased we were able to se­cure the long-term ca­pac­i­ty we be­lieve we will need to meet the po­ten­tial glob­al de­mand for ubli­tux­imab,” TG CEO Michael Weiss said in a state­ment. “This is an im­por­tant next step in our long-stand­ing re­la­tion­ship with Sam­sung.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.